Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement
MAZE(NASDAQ:MAZE) Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement
September 11, 2025Fundraising
Read more →Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer
MAZE(NASDAQ:MAZE) SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointment of Misbah Tahir as chief financial officer (CFO), effective immediately.
September 2, 2025Management
Read more →Maze Therapeutics Q1 EPS $(1.15) Up From $(13.91) YoY
MAZEMay 14, 2025
Read more →Guggenheim Reiterates Buy on Maze Therapeutics, Maintains $19 Price Target
MAZEApril 2, 2025
Read more →Maze Therapeutics Q4 2024 GAAP EPS $(18.32) Vs. $(11.46) YoY, Raised $140M In Gross Proceeds In Upsized IPO In February 2025, Providing Expected Cash Runway Into H2 2027
MAZEMarch 31, 2025
Read more →Guggenheim Initiates Coverage On Maze Therapeutics with Buy Rating, Announces Price Target of $19
MAZEFebruary 25, 2025
Read more →Leerink Partners Initiates Coverage On Maze Therapeutics with Outperform Rating, Announces Price Target of $28
MAZEFebruary 25, 2025
Read more →JP Morgan Initiates Coverage On Maze Therapeutics with Overweight Rating, Announces Price Target of $30
MAZEFebruary 25, 2025
Read more →